AP1730A - Multiple target test useful for pre-donation screening of blood. - Google Patents

Multiple target test useful for pre-donation screening of blood.

Info

Publication number
AP1730A
AP1730A APAP/P/2003/002815A AP2003002815A AP1730A AP 1730 A AP1730 A AP 1730A AP 2003002815 A AP2003002815 A AP 2003002815A AP 1730 A AP1730 A AP 1730A
Authority
AP
ARIPO
Prior art keywords
blood
tests
targets
donation
multiple target
Prior art date
Application number
APAP/P/2003/002815A
Other versions
AP2003002815A0 (en
Inventor
Lee Helen
Jean-Pierre Allain
Original Assignee
Lee Helen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lee Helen filed Critical Lee Helen
Publication of AP2003002815A0 publication Critical patent/AP2003002815A0/en
Application granted granted Critical
Publication of AP1730A publication Critical patent/AP1730A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Tests for establishing whether any of a plurality of different targets are present in a sample solution are described. If one or more of the targets are detected a positive result is obtained, but the different targets are not differentiated by the test, so there is no indication which targets have been detected. Such tests are useful for pre-donation screening of blood at public blood donation sessions to test whether the blood is safe for transfusion. The tests allow infected blood lo be identified, but preserve the confidentiality of the reason for refusal of infected blood. This avoids the distress caused by public diagnosis of infection by diseases with which there is a social stigma attached, such as HIV. The tests are particularly suited for use in developing countries to screen for HIV. HBV, and HCV infection. Dipsticks and kits for performing the tests are also described.
APAP/P/2003/002815A 2000-12-21 2001-12-21 Multiple target test useful for pre-donation screening of blood. AP1730A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0031391.6A GB0031391D0 (en) 2000-12-21 2000-12-21 Pre-donation testing
PCT/GB2001/005792 WO2002050544A1 (en) 2000-12-21 2001-12-21 Multiple target test useful for pre-donation screening of blood

Publications (2)

Publication Number Publication Date
AP2003002815A0 AP2003002815A0 (en) 2003-06-30
AP1730A true AP1730A (en) 2007-03-30

Family

ID=9905695

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2003/002815A AP1730A (en) 2000-12-21 2001-12-21 Multiple target test useful for pre-donation screening of blood.

Country Status (6)

Country Link
CN (1) CN1486425A (en)
AP (1) AP1730A (en)
AU (1) AU2002216285A1 (en)
GB (1) GB0031391D0 (en)
OA (1) OA12487A (en)
WO (1) WO2002050544A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007006885A (en) 2004-12-13 2007-08-20 Bayer Healthcare Llc Self-contained test sensor.
CN101246168B (en) * 2008-01-29 2013-07-24 马义才 Portable venereal disease all-in-one fast joint inspection device
CN114599977A (en) * 2019-12-30 2022-06-07 深圳迈瑞生物医疗电子股份有限公司 Kit and method for detecting infectious diseases and immunoassay instrument

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023299A1 (en) * 1993-03-31 1994-10-13 Quidel Corporation Multiple assay device
WO1997034148A1 (en) * 1996-03-14 1997-09-18 Spectral Diagnostics, Inc. Immunoassay device
US5770460A (en) * 1991-01-11 1998-06-23 Quidel Corporation One-step lateral flow nonbibulous assay

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141850A (en) * 1990-02-07 1992-08-25 Hygeia Sciences, Inc. Porous strip form assay device method
EP0705426A4 (en) * 1993-06-09 1998-07-08 Quidel Corp Antigen-specific one-step assays
WO1995027081A1 (en) * 1994-03-31 1995-10-12 E.I. Du Pont De Nemours And Company A method for detection of nucleic acid fragments
CA2207759A1 (en) * 1994-12-22 1996-06-27 Abbott Laboratories Differential timing method for detecting multiple analytes in a test sample
US5741662A (en) * 1995-12-18 1998-04-21 Quidel Corporation Direct stain specific binding assays for microorganisms
WO1998036278A1 (en) * 1997-02-15 1998-08-20 Beth Israel Deaconess Medical Center, Inc. Multiple-site antibody capture immunoassays and kits

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770460A (en) * 1991-01-11 1998-06-23 Quidel Corporation One-step lateral flow nonbibulous assay
WO1994023299A1 (en) * 1993-03-31 1994-10-13 Quidel Corporation Multiple assay device
WO1997034148A1 (en) * 1996-03-14 1997-09-18 Spectral Diagnostics, Inc. Immunoassay device

Also Published As

Publication number Publication date
OA12487A (en) 2006-05-24
AP2003002815A0 (en) 2003-06-30
GB0031391D0 (en) 2001-02-07
AU2002216285A1 (en) 2002-07-01
WO2002050544A1 (en) 2002-06-27
CN1486425A (en) 2004-03-31

Similar Documents

Publication Publication Date Title
Choudhury et al. Transfusion transmitted diseases
AP1730A (en) Multiple target test useful for pre-donation screening of blood.
Cilliers et al. Human immunodeficiency virus in cadavers: A review
ShrivaSTava et al. Nucleic Acid Amplification testing (NAT): An innovative Diagnostic approach for enhancing blood safety
Sultana et al. Hepatitis C virus genotypes in injecting drug users from Romania
El-Moselhy et al. Prevalence and risk factors of overt-and occult hepatitis C virus infection among chronic kidney disease patients under regular hemodialysis in Egypt
Shah et al. Prevalence of HIV-I/II, HCV, HBsAg& Syphilis in Blood Donors Of Western Region In India.
Panhotra et al. Visual detection of multiple viral amplicons by dipstick assay: its application in screening of blood donors a welcome tool for the limited resource settings
Radhiga et al. Patterns of transfusion transmitted infection in past ten years among voluntary blood donors in Chennai-a cross sectional study
Gańczak et al. Rationale against preoperative screening for HIV in Polish hospitals: a prevalence study of anti-HIV in contrast to anti-hepatitis C virus and hepatitis B surface antigen
Sukrutha Gopal et al. Seroprevalence of transfusion transmissible infections among healthy blood donors at KIMS blood bank
Hassan Egyptian Children with Malignancy
Chhetri Sero-prevalence of transfusion transmitted infections among blood donors at CRRH, Gelephu, Bhutan
Brojer Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology in Poland
Gomes et al. Evaluation of association of demographic profiles and sero prevalence of HBV and HCV among the patients presenting with chronic liver disease and its complications: A Tertiary Care Hospital Based Study
Israr et al. Seroprevalence and risk factors of hepatitis B virus among blood donors in district Charsadda Khyber Pakhtunkhwa Pakistan
Barbara Transfusion‐Transmitted Infections
Binhazim et al. Spontaneous anaplastic large cell lymphoma in a chimpanzee: a clinicopathological and immunohistochemical study
Sarkar et al. Erythrocyte sedimentation rate may be an indicator for screening of tuberculosis patients for underlying HIV infection, particularly in resource-poor settings: an experience from India
Nwokedi et al. Hepatitis C virus infection among Teaching Hospital patients in Kano, Nigeria: A retrospective study
Pathak et al. Evaluation of the seroprevalence of transfusion transmissible infections among blood donors in a tertiary care hospital of North India
DK1044377T3 (en) Procedure for detection of Borna disease virus (BDV) infections
Seme et al. Twenty-four mini-pool HCV RNA screening outside a blood transfusion setting: Results of a 2-year prospective study
Seme et al. Twenty-four mini-pool HCV RNA screening in a routine clinical virology laboratory setting: A six-year prospective study
CN111579779B (en) Marker for evaluating immune cell function of hepatitis B patient and application thereof